Assessing multiple therapeutic targets, the authors showed that both inhibition of CDK4-6 through Palbociclib and inhibition of the PI3K/AKT signaling pathway through BEZ-235 enable the induction of cell cycle arrest at G1 phase, inhibiting cell proliferation, thus being relevant for further studies as therapeutic agents for BIA-ALCL [51]. Here, AKT1 is linked to anaplastic large cell lymphoma.